|
English
|
正體中文
|
简体中文
|
总笔数 :0
|
|
造访人次 :
53316007
在线人数 :
1114
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"shapira frommer"的相关文件
显示项目 1-3 / 3 (共1页)
1
每页显示[10|25|50]项目
| 國立成功大學 |
2024-09 |
Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
|
Shapira-Frommer;R;Sudo;K;Harano;K;Mileshkin;L;Perets;R;Song;M;Cohen;J;Huang;Y-F;Ambrose;H;Brier;T;Dosani;A;Fraenkel;P, G.;Kmieciak;A;Mitchell;P;Myers;C;Wang;J;Odegbami;R, I.;Sykes;A;Turner;S;Meric-Bernstam;F |
| 國立成功大學 |
2024-09 |
Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
|
Toullec;C;Seo;S;Robinson;A, G.;Chou;H-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Aksoy;S;Ochsenreither;S;Ruiz;Yanez, E. P.;Rha;S, Y.;Shapira-Frommer;R;Liu;Q;Plessis, Du;M;Keenan;T;Hsu;C-H |
| 國立成功大學 |
2024-09 |
Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005
|
Seo;S;Calderon;B;Chou;H-H;Hsu;C-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Shapira-Frommer;R;Rha;S, Y.;Zhang;Y;Chen;C;Pena;C, E.;Keenan;T;Chen;Y;Dettman;E;Robinson;A, G. |
显示项目 1-3 / 3 (共1页)
1
每页显示[10|25|50]项目
|
